Details

---

Manufacturer
Ind-Swift Limited, India

Registraction Number
MAL20000072AZ




Content

• Active Ingredient: Ivabradine 5 mg

Indications
Ivaswift 5mg tablets are indicated for:

• Symptomatic Treatment of Chronic Stable Angina Pectoris: In adults with coronary artery disease and normal sinus rhythm, who have a resting heart rate ≥70 bpm.
• Chronic Heart Failure: In adults with chronic heart failure (NYHA class II–IV), systolic dysfunction, and a resting heart rate ≥75 bpm, in combination with standard therapy, including beta-blockers, or when beta-blockers are contraindicated or not tolerated.

Instructions for Use

• Dosage:
  • Chronic Stable Angina Pectoris:
    • Starting dose: 5 mg twice daily.
    • After 3–4 weeks, if symptoms persist and heart rate remains above 60 bpm, the dose may be increased to 7.5 mg twice daily.
    • If no improvement after 3 months, consider discontinuing treatment.
  • Chronic Heart Failure:
    • Starting dose: 5 mg twice daily.
    • After 2 weeks, adjust the dose to achieve a resting heart rate between 50–60 bpm.
    • Maximum dose: 7.5 mg twice daily.
    • If heart rate remains below 50 bpm or symptoms of bradycardia occur, reduce the dose to 2.5 mg twice daily or discontinue treatment.
• Administration:
  • Take with food to enhance absorption.
  • Swallow tablets whole; do not chew or crush.
• Precautions:
  • Use with caution in patients with mild to moderate hepatic insufficiency.
  • Not recommended for patients with severe hepatic insufficiency.
  • Monitor heart rate regularly during treatment.